Cargando…

The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses

Pre-existing cross-reactive immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by several studies. In particular, regions of high homology between SARS-CoV-2 and common cold coronaviruses have been highlighted as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murray, Sam M., Ansari, Azim M., Frater, John, Klenerman, Paul, Dunachie, Susanna, Barnes, Eleanor, Ogbe, Ane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765363/ https://www.ncbi.nlm.nih.gov/pubmed/36539527 http://dx.doi.org/10.1038/s41577-022-00809-x

Ejemplares similares

SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study
por: Ward, Victoria, et al.
Publicado: (2022)

Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-attenuated influenza vaccines in UK adolescents
por: Jay, Cecilia, et al.
Publicado: (2023)

SARS-CoV-2: the emergence of a viral pathogen causing havoc on human existence
por: Prasad, Ashish, et al.
Publicado: (2020)

Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members
por: Jay, Cecilia, et al.
Publicado: (2023)

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
por: Ogbe, Ane, et al.
Publicado: (2021)

Cross-reactive memory T cells and herd immunity to SARS-CoV-2
por: Lipsitch, Marc, et al.
Publicado: (2020)

Evidence and implications of pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2
por: Mveang Nzoghe, Amandine, et al.
Publicado: (2020)

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia
por: Lee, Eun-Ju, et al.
Publicado: (2021)

Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients
por: Anft, Moritz, et al.
Publicado: (2021)

Metabolic effects of milk protein intake strongly depend on pre-existing metabolic and exercise status
por: Melnik, Bodo C, et al.
Publicado: (2013)

Distinguishing SARS-CoV-2 bonafide re-infection from pre-existing minor variant reactivation
por: Siqueira, Juliana D., et al.
Publicado: (2021)

What Are the Prospects for Controlling Hepatitis C?
por: Klenerman, Paul, et al.
Publicado: (2009)

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals
por: Longet, Stephanie, et al.
Publicado: (2022)

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
por: Skelly, Donal T., et al.
Publicado: (2021)

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
por: Fidler, Sarah, et al.
Publicado: (2022)

Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies
por: Rouzine, Igor M., et al.
Publicado: (2023)

Defining the key intrahepatic gene networks in HCV infection driven by sex
por: Marchi, Emanuele, et al.
Publicado: (2023)

Susceptibility to reinfection with SARS-CoV-2 virus relative to existing antibody concentrations and T cell response
por: Atef, Shereen, et al.
Publicado: (2023)

Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers
por: Phillips, Eloise, et al.
Publicado: (2022)

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
por: Angyal, Adrienn, et al.
Publicado: (2022)

Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination
por: Johnson, Síle A, et al.
Publicado: (2023)

Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity
por: Izmirly, Abdullah M., et al.
Publicado: (2020)

Vaccination against SARS-CoV-2 and disease enhancement – knowns and unknowns
por: Zellweger, Raphaël M., et al.
Publicado: (2020)

Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a
por: Pedergnana, Vincent, et al.
Publicado: (2016)

Approaches and Challenges in SARS-CoV-2 Vaccine Development
por: Dagotto, Gabriel, et al.
Publicado: (2020)

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Adapting Serosurveys for the SARS-CoV-2 Vaccine Era
por: Duarte, Nathan, et al.
Publicado: (2021)

The Erosion of Public Trust and SARS-CoV-2 Vaccines— More Action Is Needed
por: Nahum, Ari, et al.
Publicado: (2021)

1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE
por: Wellens, Judith, et al.
Publicado: (2022)

Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 Vaccination
por: Amraotkar, Alok R., et al.
Publicado: (2022)

SARS-CoV-2 vaccine boosters: The time to act is now
por: Petersen, Maya, et al.
Publicado: (2021)

Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
por: Sette, Alessandro, et al.
Publicado: (2020)

Divergent trajectories of antiviral memory after SARS-CoV-2 infection
por: Tomic, Adriana, et al.
Publicado: (2022)

Aging and CMV Infection Affect Pre-existing SARS-CoV-2-Reactive CD8(+) T Cells in Unexposed Individuals
por: Jo, Norihide, et al.
Publicado: (2021)

Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action()
por: Yousefi, Hassan, et al.
Publicado: (2021)

A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117
por: Zacharopoulou, Panagiota, et al.
Publicado: (2022)

mRNA Vaccines: Possible Tools to Combat SARS-CoV-2
por: Yi, Changhua, et al.
Publicado: (2020)

Considerations for the Selection and Use of Disinfectants Against SARS-CoV-2 in a Health Care Setting
por: Tyan, Kevin, et al.
Publicado: (2020)

SARS-CoV-2 vaccination in the immunocompromised host
por: Connolly, Caoilfhionn M., et al.
Publicado: (2022)

Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination
por: Hu, Caiqin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hlcttv4co35rp7hgmqgdj3a4a3